Prova Storytel gratis i 30 dagar Ett universum fyllt av ljudböcker, klicka här för att komma igång

This Week in Addiction Medicine from ASAM

En podcast av: American Society of Addiction Medicine

A podcast source for news briefings on the top stories in the field of addiction medicine.

Our American listeners can also listen to This Week in Addiction Medicine from ASAM at our American site

153 Avsnitt

Lead: The association between buprenorphine doses above 16 milligrams and treatment retention in a multi-payer national sample in the United States, 2014 to 2021
Publicerades 2025-03-11

Lead: Illicit Substance Use and Treatment Access Among Adults Experiencing Homelessness
Publicerades 2025-03-04
Lead: Once-Weekly Semaglutide in Adults With Alcohol Use Disorder
Publicerades 2025-02-25
Lead: Cannabis Use Disorder Emergency Department Visits and Hospitalizations and 5-Year Mortality
Publicerades 2025-02-19
Lead: Real-Time Assessment of Alcohol Reward, Stimulation, and Negative Affect in Individuals With and Without Alcohol Use Disorder and Depressive Disorders
Publicerades 2025-02-11
Lead: Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl
Publicerades 2025-02-04
Lead: Association of State Cannabis Legalization With Cannabis Use Disorder and Cannabis Poisoning
Publicerades 2025-01-28
Lead: Current Advances in Behavioral Addictions: From Fundamental Research to Clinical Practice
Publicerades 2025-01-21
ASAM Weekly Special Episode: Dr. David Fiellin & Dr. Eric Strain sit down to discuss the concept of Treatment Refractory Addiction
Publicerades 2025-01-14
Lead: Review of Evidence on Alcohol and Health
Publicerades 2025-01-14
Lead: The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies
Publicerades 2024-12-17
Lead: Prevalence of pharmacotherapy for attention-deficit/hyperactivity disorder and prescription stimulant misuse: A national study of US college students
Publicerades 2024-12-10
Lead: Xylazine Pharmacokinetics in Patients Testing Positive for Fentanyl and Xylazine
Publicerades 2024-12-04
Lead: Suicide in people prescribed opioid-agonist therapy in Scotland, United Kingdom, 2011–2020: A national retrospective cohort study
Publicerades 2024-11-19
Lead: Links between adolescent binge drinking and midlife alcohol use behaviors by age, sex, and race/ethnicity
Publicerades 2024-11-05
Lead: Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder
Publicerades 2024-10-29
Lead: Association of Daily Doses of Buprenorphine With Urgent Health Care Utilization
Publicerades 2024-10-22
Lead: Facilitators of and barriers to buprenorphine initiation in the emergency department: a scoping review
Publicerades 2024-10-15
Lead: Cannabis Policy Impacts Public Health and Health Equity
Publicerades 2024-10-08
ASAM Weekly Special Episode: Dr. Shannon Miller talks PAM-7 and his path to addiction medicine [From the ASAM 55th Annual Conference]
Publicerades 2024-09-30

A podcast source for news briefings on the top stories in the field of addiction medicine.

153 Avsnitt

Lead: The association between buprenorphine doses above 16 milligrams and treatment retention in a multi-payer national sample in the United States, 2014 to 2021

Lead: Illicit Substance Use and Treatment Access Among Adults Experiencing Homelessness

Lead: Once-Weekly Semaglutide in Adults With Alcohol Use Disorder

Lead: Cannabis Use Disorder Emergency Department Visits and Hospitalizations and 5-Year Mortality

Lead: Real-Time Assessment of Alcohol Reward, Stimulation, and Negative Affect in Individuals With and Without Alcohol Use Disorder and Depressive Disorders

Lead: Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl

Lead: Association of State Cannabis Legalization With Cannabis Use Disorder and Cannabis Poisoning

Lead: Current Advances in Behavioral Addictions: From Fundamental Research to Clinical Practice

ASAM Weekly Special Episode: Dr. David Fiellin & Dr. Eric Strain sit down to discuss the concept of Treatment Refractory Addiction

Lead: Review of Evidence on Alcohol and Health

Lead: The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies

Lead: Prevalence of pharmacotherapy for attention-deficit/hyperactivity disorder and prescription stimulant misuse: A national study of US college students

Lead: Xylazine Pharmacokinetics in Patients Testing Positive for Fentanyl and Xylazine

Lead: Suicide in people prescribed opioid-agonist therapy in Scotland, United Kingdom, 2011–2020: A national retrospective cohort study

Lead: Links between adolescent binge drinking and midlife alcohol use behaviors by age, sex, and race/ethnicity

Lead: Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder

Lead: Association of Daily Doses of Buprenorphine With Urgent Health Care Utilization

Lead: Facilitators of and barriers to buprenorphine initiation in the emergency department: a scoping review

Lead: Cannabis Policy Impacts Public Health and Health Equity

ASAM Weekly Special Episode: Dr. Shannon Miller talks PAM-7 and his path to addiction medicine [From the ASAM 55th Annual Conference]